Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation

Nobuko Serizawa, Jijing Tian, Hiroo Fukada, Kornelia Baghy, Fiona Scott, Xiangling Chen, Zsofia Kiss, Kristin A Olson, Dan Hsu, Fu-Tong Liu, Natalia J Torok, Bin Zhao, Xiaosong Jiang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) carries a poor prognosis with no effective treatment available other than liver transplantation for selected patients. Vascular invasion of HCC is one of the most important negative predictor of survival. As the regulation of invasion of HCC cells is not well understood, our aim was to study the mechanisms by which galectin 3, a β-galactosidase-binding lectin mediates HCC cell migration. HCC was induced by N-diethylnitrosamine in wild-type and galectin 3 -/- mice, and tumor formation, histology, and tumor cell invasion were assessed. The galectin 3 -/- mice developed significantly smaller tumor burden with a less invasive phenotype than the wild-type animals. Galectin 3 was upregulated in the wild-type HCC tumor tissue, but not in the surrounding parenchyma. Galectin 3 expression in HCC was induced by NF-κB transactivation as determined by chromatin immunoprecipitation assays. In vitro studies assessed the pro-migratory effects of galectin 3. The migration of hepatoma cells was significantly decreased after transfection by the galectin 3 siRNA and also after using the Rho kinase inhibitor Y-27632. The reorganization of the actin cytoskeleton, RhoA GTPase activity and the phosphorylation of MLC2 (myosin light chain 2) were decreased in the galectin 3 siRNA-transfected cells. In addition, in vitro and in vivo evidence showed that galectin 3 deficiency reduced hepatoma cell proliferation and increased their apoptosis rate. In conclusion, galectin 3 is an important lectin that is induced in HCC cells, and promotes hepatoma cell motility and invasion by an autocrine pathway. Targeting galectin 3 therefore could be an important novel treatment strategy to halt disease progression.

Original languageEnglish (US)
Pages (from-to)1145-1156
Number of pages12
JournalLaboratory Investigation
Volume95
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Galectin 3
Hepatocellular Carcinoma
Cell Movement
Lectins
Small Interfering RNA
Galactosidases
Diethylnitrosamine
rho-Associated Kinases
Neoplasms
Wild Animals
Chromatin Immunoprecipitation
GTP Phosphohydrolases
Tumor Burden
Actin Cytoskeleton
Liver Transplantation
Transcriptional Activation
Transfection
Blood Vessels
Disease Progression
Histology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

Serizawa, N., Tian, J., Fukada, H., Baghy, K., Scott, F., Chen, X., ... Jiang, X. (2015). Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Laboratory Investigation, 95(10), 1145-1156. https://doi.org/10.1038/labinvest.2015.77

Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. / Serizawa, Nobuko; Tian, Jijing; Fukada, Hiroo; Baghy, Kornelia; Scott, Fiona; Chen, Xiangling; Kiss, Zsofia; Olson, Kristin A; Hsu, Dan; Liu, Fu-Tong; Torok, Natalia J; Zhao, Bin; Jiang, Xiaosong.

In: Laboratory Investigation, Vol. 95, No. 10, 01.10.2015, p. 1145-1156.

Research output: Contribution to journalArticle

Serizawa, N, Tian, J, Fukada, H, Baghy, K, Scott, F, Chen, X, Kiss, Z, Olson, KA, Hsu, D, Liu, F-T, Torok, NJ, Zhao, B & Jiang, X 2015, 'Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation', Laboratory Investigation, vol. 95, no. 10, pp. 1145-1156. https://doi.org/10.1038/labinvest.2015.77
Serizawa N, Tian J, Fukada H, Baghy K, Scott F, Chen X et al. Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Laboratory Investigation. 2015 Oct 1;95(10):1145-1156. https://doi.org/10.1038/labinvest.2015.77
Serizawa, Nobuko ; Tian, Jijing ; Fukada, Hiroo ; Baghy, Kornelia ; Scott, Fiona ; Chen, Xiangling ; Kiss, Zsofia ; Olson, Kristin A ; Hsu, Dan ; Liu, Fu-Tong ; Torok, Natalia J ; Zhao, Bin ; Jiang, Xiaosong. / Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. In: Laboratory Investigation. 2015 ; Vol. 95, No. 10. pp. 1145-1156.
@article{c9a78b768058482f88fa377a577aae18,
title = "Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation",
abstract = "Hepatocellular carcinoma (HCC) carries a poor prognosis with no effective treatment available other than liver transplantation for selected patients. Vascular invasion of HCC is one of the most important negative predictor of survival. As the regulation of invasion of HCC cells is not well understood, our aim was to study the mechanisms by which galectin 3, a β-galactosidase-binding lectin mediates HCC cell migration. HCC was induced by N-diethylnitrosamine in wild-type and galectin 3 -/- mice, and tumor formation, histology, and tumor cell invasion were assessed. The galectin 3 -/- mice developed significantly smaller tumor burden with a less invasive phenotype than the wild-type animals. Galectin 3 was upregulated in the wild-type HCC tumor tissue, but not in the surrounding parenchyma. Galectin 3 expression in HCC was induced by NF-κB transactivation as determined by chromatin immunoprecipitation assays. In vitro studies assessed the pro-migratory effects of galectin 3. The migration of hepatoma cells was significantly decreased after transfection by the galectin 3 siRNA and also after using the Rho kinase inhibitor Y-27632. The reorganization of the actin cytoskeleton, RhoA GTPase activity and the phosphorylation of MLC2 (myosin light chain 2) were decreased in the galectin 3 siRNA-transfected cells. In addition, in vitro and in vivo evidence showed that galectin 3 deficiency reduced hepatoma cell proliferation and increased their apoptosis rate. In conclusion, galectin 3 is an important lectin that is induced in HCC cells, and promotes hepatoma cell motility and invasion by an autocrine pathway. Targeting galectin 3 therefore could be an important novel treatment strategy to halt disease progression.",
author = "Nobuko Serizawa and Jijing Tian and Hiroo Fukada and Kornelia Baghy and Fiona Scott and Xiangling Chen and Zsofia Kiss and Olson, {Kristin A} and Dan Hsu and Fu-Tong Liu and Torok, {Natalia J} and Bin Zhao and Xiaosong Jiang",
year = "2015",
month = "10",
day = "1",
doi = "10.1038/labinvest.2015.77",
language = "English (US)",
volume = "95",
pages = "1145--1156",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation

AU - Serizawa, Nobuko

AU - Tian, Jijing

AU - Fukada, Hiroo

AU - Baghy, Kornelia

AU - Scott, Fiona

AU - Chen, Xiangling

AU - Kiss, Zsofia

AU - Olson, Kristin A

AU - Hsu, Dan

AU - Liu, Fu-Tong

AU - Torok, Natalia J

AU - Zhao, Bin

AU - Jiang, Xiaosong

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Hepatocellular carcinoma (HCC) carries a poor prognosis with no effective treatment available other than liver transplantation for selected patients. Vascular invasion of HCC is one of the most important negative predictor of survival. As the regulation of invasion of HCC cells is not well understood, our aim was to study the mechanisms by which galectin 3, a β-galactosidase-binding lectin mediates HCC cell migration. HCC was induced by N-diethylnitrosamine in wild-type and galectin 3 -/- mice, and tumor formation, histology, and tumor cell invasion were assessed. The galectin 3 -/- mice developed significantly smaller tumor burden with a less invasive phenotype than the wild-type animals. Galectin 3 was upregulated in the wild-type HCC tumor tissue, but not in the surrounding parenchyma. Galectin 3 expression in HCC was induced by NF-κB transactivation as determined by chromatin immunoprecipitation assays. In vitro studies assessed the pro-migratory effects of galectin 3. The migration of hepatoma cells was significantly decreased after transfection by the galectin 3 siRNA and also after using the Rho kinase inhibitor Y-27632. The reorganization of the actin cytoskeleton, RhoA GTPase activity and the phosphorylation of MLC2 (myosin light chain 2) were decreased in the galectin 3 siRNA-transfected cells. In addition, in vitro and in vivo evidence showed that galectin 3 deficiency reduced hepatoma cell proliferation and increased their apoptosis rate. In conclusion, galectin 3 is an important lectin that is induced in HCC cells, and promotes hepatoma cell motility and invasion by an autocrine pathway. Targeting galectin 3 therefore could be an important novel treatment strategy to halt disease progression.

AB - Hepatocellular carcinoma (HCC) carries a poor prognosis with no effective treatment available other than liver transplantation for selected patients. Vascular invasion of HCC is one of the most important negative predictor of survival. As the regulation of invasion of HCC cells is not well understood, our aim was to study the mechanisms by which galectin 3, a β-galactosidase-binding lectin mediates HCC cell migration. HCC was induced by N-diethylnitrosamine in wild-type and galectin 3 -/- mice, and tumor formation, histology, and tumor cell invasion were assessed. The galectin 3 -/- mice developed significantly smaller tumor burden with a less invasive phenotype than the wild-type animals. Galectin 3 was upregulated in the wild-type HCC tumor tissue, but not in the surrounding parenchyma. Galectin 3 expression in HCC was induced by NF-κB transactivation as determined by chromatin immunoprecipitation assays. In vitro studies assessed the pro-migratory effects of galectin 3. The migration of hepatoma cells was significantly decreased after transfection by the galectin 3 siRNA and also after using the Rho kinase inhibitor Y-27632. The reorganization of the actin cytoskeleton, RhoA GTPase activity and the phosphorylation of MLC2 (myosin light chain 2) were decreased in the galectin 3 siRNA-transfected cells. In addition, in vitro and in vivo evidence showed that galectin 3 deficiency reduced hepatoma cell proliferation and increased their apoptosis rate. In conclusion, galectin 3 is an important lectin that is induced in HCC cells, and promotes hepatoma cell motility and invasion by an autocrine pathway. Targeting galectin 3 therefore could be an important novel treatment strategy to halt disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84942815047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942815047&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2015.77

DO - 10.1038/labinvest.2015.77

M3 - Article

C2 - 26146960

AN - SCOPUS:84942815047

VL - 95

SP - 1145

EP - 1156

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 10

ER -